11 June 2019 - - A pre-specified exploratory analysis of renal data from the Phase III DECLARE-TIMI 58 trial, the broadest cardiovascular outcomes trial of a sodium-glucose co-transporter 2 (SGLT2) inhibitor, showed that Farxiga (dapagliflozin) reduced the progression of kidney disease or renal death in patients with type 2 diabetes, British-Swedish drugmaker AstraZeneca said.
These data, presented at the American Diabetes Association 79th Scientific Sessions, San Francisco, USA, and simultaneously published in The Lancet Diabetes and Endocrinology, showed a 47% reduction with Farxiga in the relative risk of the composite renal-specific outcome of kidney function decline (sustained ≥40% decrease in estimated glomerular filtration rate [eGFR] to